3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cytarabine
7
Daunorubicin
5
Azacitidine
5
venetoclax
3
Decitabine
3
ivosidenib
2
decitabine and cedazuridine drug combination
2
cedazuridine
2
Mitoxantrone
2
Idarubicin
2
Etoposide
2
treosulfan
1
tagraxofusp
1
revumenib
1
quizartinib
1
olutasidenib
1
glasdegib
1
gilteritinib
1
fludarabine
1
etoposide phosphate
1
enasidenib
1
cc-486
1
Midazolam
1
Itraconazole
1
Granulocyte Colony-Stimulating Factor
1
Gemtuzumab
1
Drug Therapy
1
Cobicistat
1
CPX-351
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Leukemia, Myeloid, Acute
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA